CN105612162B - 作为nmda受体活性的调节剂的噻唑并嘧啶酮类 - Google Patents
作为nmda受体活性的调节剂的噻唑并嘧啶酮类 Download PDFInfo
- Publication number
- CN105612162B CN105612162B CN201480055668.4A CN201480055668A CN105612162B CN 105612162 B CN105612162 B CN 105612162B CN 201480055668 A CN201480055668 A CN 201480055668A CN 105612162 B CN105612162 B CN 105612162B
- Authority
- CN
- China
- Prior art keywords
- methyl
- pyrimidine
- trifluoromethyl
- ketone
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(*1C(C=C(*)COc(cc2)ccc2N)=O)NC(C)=C1C(OC)=O Chemical compound CC(*1C(C=C(*)COc(cc2)ccc2N)=O)NC(C)=C1C(OC)=O 0.000 description 9
- FJFBEVGGFJCNMY-UHFFFAOYSA-N CC(C(N12)=C(C)SC1=NC(C[n]1nc(C(F)(F)F)cc1)=CC2=O)O Chemical compound CC(C(N12)=C(C)SC1=NC(C[n]1nc(C(F)(F)F)cc1)=CC2=O)O FJFBEVGGFJCNMY-UHFFFAOYSA-N 0.000 description 1
- ITXUBEXPFBRJMB-UHFFFAOYSA-N CC(C1)C1C(N12)=C(C)SC1=NC(COc(cc1)ccc1F)=CC2=O Chemical compound CC(C1)C1C(N12)=C(C)SC1=NC(COc(cc1)ccc1F)=CC2=O ITXUBEXPFBRJMB-UHFFFAOYSA-N 0.000 description 1
- IXXQLVVMNITSAS-UHFFFAOYSA-N CC(SC(N12)=NC(C[n](c(Cl)c3)nc3[N+]([O-])=O)=CC1=O)=C2Br Chemical compound CC(SC(N12)=NC(C[n](c(Cl)c3)nc3[N+]([O-])=O)=CC1=O)=C2Br IXXQLVVMNITSAS-UHFFFAOYSA-N 0.000 description 1
- KPQVWYBVLXOKCI-UHFFFAOYSA-N CC(SC1=NC(COc(cc2)ccc2F)=C2)=C(CCl)N1C2=O Chemical compound CC(SC1=NC(COc(cc2)ccc2F)=C2)=C(CCl)N1C2=O KPQVWYBVLXOKCI-UHFFFAOYSA-N 0.000 description 1
- YNSDFULSRUQGEI-UHFFFAOYSA-N CC(SC1=NC(COc(cc2)ccc2F)=C2F)=C(C3C(CO)C3)N1C2=[U] Chemical compound CC(SC1=NC(COc(cc2)ccc2F)=C2F)=C(C3C(CO)C3)N1C2=[U] YNSDFULSRUQGEI-UHFFFAOYSA-N 0.000 description 1
- ZQBKFVPBMDFMAA-UHFFFAOYSA-N CC(SC1=NC(C[n](c(Cl)c2)nc2Cl)=C2)=C(C(C3)C3C#N)N1C2=O Chemical compound CC(SC1=NC(C[n](c(Cl)c2)nc2Cl)=C2)=C(C(C3)C3C#N)N1C2=O ZQBKFVPBMDFMAA-UHFFFAOYSA-N 0.000 description 1
- QFIKJXWLQXBBNF-UHFFFAOYSA-N CC(SC1=NC(C[n]2nc(C3CC3)c(F)c2C(F)(F)F)=C2)=C(C3C(CO)C3)N1C2=O Chemical compound CC(SC1=NC(C[n]2nc(C3CC3)c(F)c2C(F)(F)F)=C2)=C(C3C(CO)C3)N1C2=O QFIKJXWLQXBBNF-UHFFFAOYSA-N 0.000 description 1
- FEGRQSMGOJQUIV-UHFFFAOYSA-N CC(SC1=NC(Cc(cccc2C(F)(F)F)c2F)=C2)=C(C(N)=O)N1C2=O Chemical compound CC(SC1=NC(Cc(cccc2C(F)(F)F)c2F)=C2)=C(C(N)=O)N1C2=O FEGRQSMGOJQUIV-UHFFFAOYSA-N 0.000 description 1
- YHZQTMLLXVLFGA-UHFFFAOYSA-N CC(SC1=NC(Cc(cccc2C(F)(F)F)c2F)=C2)=C(c3ncc[nH]3)N1C2=O Chemical compound CC(SC1=NC(Cc(cccc2C(F)(F)F)c2F)=C2)=C(c3ncc[nH]3)N1C2=O YHZQTMLLXVLFGA-UHFFFAOYSA-N 0.000 description 1
- ORMJLGRRAOIFAS-UHFFFAOYSA-N CC(SC1=NC(Cc2cc(C#N)ccc2)=C2)=C(C(C3)C3C#N)N1C2=O Chemical compound CC(SC1=NC(Cc2cc(C#N)ccc2)=C2)=C(C(C3)C3C#N)N1C2=O ORMJLGRRAOIFAS-UHFFFAOYSA-N 0.000 description 1
- TUZKKRCAJDFAPC-UHFFFAOYSA-N CC(SC1=NC(Cc2cc(C(F)(F)F)ccc2)=C2)=C(c3cncnc3)N1C2=O Chemical compound CC(SC1=NC(Cc2cc(C(F)(F)F)ccc2)=C2)=C(c3cncnc3)N1C2=O TUZKKRCAJDFAPC-UHFFFAOYSA-N 0.000 description 1
- TUXCUWZCFQDMLZ-UHFFFAOYSA-N CC1C(B2OC(C)(C)C(C)(C)O2)C1 Chemical compound CC1C(B2OC(C)(C)C(C)(C)O2)C1 TUXCUWZCFQDMLZ-UHFFFAOYSA-N 0.000 description 1
- AVZONORTIKANFD-UHFFFAOYSA-N CCN(CC(N=C1SC(C(C)(C)CC2)=C2N11)=CC1=O)c(cc1)ccc1F Chemical compound CCN(CC(N=C1SC(C(C)(C)CC2)=C2N11)=CC1=O)c(cc1)ccc1F AVZONORTIKANFD-UHFFFAOYSA-N 0.000 description 1
- RKLNEZQSWAPOIQ-ZHACJKMWSA-N CCN(CC(N=C1SC(C)=C(/C=C/C(OCC)=O)N11)=CC1=O)c(cc1)ccc1F Chemical compound CCN(CC(N=C1SC(C)=C(/C=C/C(OCC)=O)N11)=CC1=O)c(cc1)ccc1F RKLNEZQSWAPOIQ-ZHACJKMWSA-N 0.000 description 1
- JMSWSCNQGGVQSF-UHFFFAOYSA-N CCN(CC(N=C1SC(C)=C(C(C2)C2C(N)=O)N11)=CC1=O)c(cc1)ccc1F Chemical compound CCN(CC(N=C1SC(C)=C(C(C2)C2C(N)=O)N11)=CC1=O)c(cc1)ccc1F JMSWSCNQGGVQSF-UHFFFAOYSA-N 0.000 description 1
- IRNFSEHDPRHDTN-UHFFFAOYSA-N CCN(CC(N=C1SC(C)=C(C(C2)C2C(O)=O)N11)=CC1=O)c(cc1)ccc1F Chemical compound CCN(CC(N=C1SC(C)=C(C(C2)C2C(O)=O)N11)=CC1=O)c(cc1)ccc1F IRNFSEHDPRHDTN-UHFFFAOYSA-N 0.000 description 1
- NANCFADVIHSXEF-UHFFFAOYSA-N CCN(CC(N=C1SC(C)=C(CCO)N11)=CC1=O)c(cc1)ccc1F Chemical compound CCN(CC(N=C1SC(C)=C(CCO)N11)=CC1=O)c(cc1)ccc1F NANCFADVIHSXEF-UHFFFAOYSA-N 0.000 description 1
- BAYSQWBBVAVGPS-UHFFFAOYSA-N CCN(CC(N=C1SC(C)=C(CN(C)C)N11)=CC1=O)c(cc1)ccc1F Chemical compound CCN(CC(N=C1SC(C)=C(CN(C)C)N11)=CC1=O)c(cc1)ccc1F BAYSQWBBVAVGPS-UHFFFAOYSA-N 0.000 description 1
- IICSURZSJCKICX-UHFFFAOYSA-N CCOC(C(CC1)C(N23)=C1SC2=NC(CCl)=CC3=O)=O Chemical compound CCOC(C(CC1)C(N23)=C1SC2=NC(CCl)=CC3=O)=O IICSURZSJCKICX-UHFFFAOYSA-N 0.000 description 1
- POCYJQITDWDVCD-UHFFFAOYSA-N CN(C)S([n]1nc(C(F)(F)F)cc1Cl)(=N)=O Chemical compound CN(C)S([n]1nc(C(F)(F)F)cc1Cl)(=N)=O POCYJQITDWDVCD-UHFFFAOYSA-N 0.000 description 1
- WXKQWTPAQXYLRQ-UHFFFAOYSA-N O=C1N(C(Br)=C(S2)Cl)C2=NC(C[n]2nc(C(F)(F)F)cc2Cl)=C1 Chemical compound O=C1N(C(Br)=C(S2)Cl)C2=NC(C[n]2nc(C(F)(F)F)cc2Cl)=C1 WXKQWTPAQXYLRQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201480055668.4A CN105612162B (zh) | 2013-10-11 | 2014-10-08 | 作为nmda受体活性的调节剂的噻唑并嘧啶酮类 |
| CN201810852075.0A CN108929336A (zh) | 2013-10-11 | 2014-10-08 | 作为nmda受体活性的调节剂的噻唑并嘧啶酮类 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013085031 | 2013-10-11 | ||
| CNPCT/CN2013/085031 | 2013-10-11 | ||
| CN2014085959 | 2014-09-05 | ||
| CNPCT/CN2014/085959 | 2014-09-05 | ||
| CN201480055668.4A CN105612162B (zh) | 2013-10-11 | 2014-10-08 | 作为nmda受体活性的调节剂的噻唑并嘧啶酮类 |
| PCT/EP2014/071522 WO2015052226A1 (en) | 2013-10-11 | 2014-10-08 | Thiazolopyrimidinones as modulators of nmda receptor activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810852075.0A Division CN108929336A (zh) | 2013-10-11 | 2014-10-08 | 作为nmda受体活性的调节剂的噻唑并嘧啶酮类 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105612162A CN105612162A (zh) | 2016-05-25 |
| CN105612162B true CN105612162B (zh) | 2018-08-21 |
Family
ID=51688060
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480055668.4A Active CN105612162B (zh) | 2013-10-11 | 2014-10-08 | 作为nmda受体活性的调节剂的噻唑并嘧啶酮类 |
| CN201810852075.0A Pending CN108929336A (zh) | 2013-10-11 | 2014-10-08 | 作为nmda受体活性的调节剂的噻唑并嘧啶酮类 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810852075.0A Pending CN108929336A (zh) | 2013-10-11 | 2014-10-08 | 作为nmda受体活性的调节剂的噻唑并嘧啶酮类 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9988400B2 (https=) |
| EP (2) | EP3415519A1 (https=) |
| JP (2) | JP6419800B2 (https=) |
| KR (1) | KR102361108B1 (https=) |
| CN (2) | CN105612162B (https=) |
| BR (1) | BR112016007563B1 (https=) |
| CA (1) | CA2926830C (https=) |
| DK (1) | DK3055315T3 (https=) |
| ES (1) | ES2690355T3 (https=) |
| HR (1) | HRP20181596T1 (https=) |
| HU (1) | HUE040651T2 (https=) |
| LT (1) | LT3055315T (https=) |
| MX (1) | MX2016004540A (https=) |
| PL (1) | PL3055315T3 (https=) |
| PT (1) | PT3055315T (https=) |
| RS (1) | RS58047B1 (https=) |
| RU (1) | RU2703273C2 (https=) |
| SI (1) | SI3055315T1 (https=) |
| WO (1) | WO2015052226A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3283487B1 (en) * | 2015-04-15 | 2019-10-16 | H. Hoffnabb-La Roche Ag | Pyridopyrimidinones and their use as nmda receptor modulators |
| SMT202000534T1 (it) | 2015-12-09 | 2020-11-10 | Cadent Therapeutics Inc | Modulatori eteroaromatici del recettore nmda e loro usi |
| EP4006038A1 (en) | 2015-12-09 | 2022-06-01 | Cadent Therapeutics, Inc. | Thienopyrimidinone nmda receptor modulators and uses thereof |
| WO2017109709A2 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | A high-throughput assay method for identifying allosteric nmda receptor modulators |
| ES2975336T3 (es) * | 2016-12-22 | 2024-07-04 | Novartis Ag | Moduladores del receptor NMDA y usos de los mismos |
| BR112021001967A2 (pt) | 2018-08-03 | 2021-04-27 | Cadent Therapeutics, Inc. | moduladores de receptor nmda heteroaromáticos e usos dos mesmos |
| CN111840296B (zh) * | 2020-07-22 | 2021-05-04 | 华中农业大学 | 一种5H-噻唑并[3,2-a]嘧啶-5-酮类化合物在制备单胺氧化酶抑制剂中的用途 |
| CN112094267B (zh) * | 2020-08-14 | 2025-06-06 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 1-苯基-吡咯并异喹啉-3-酮类化合物及其制备方法和应用 |
| EP4032896A1 (en) * | 2021-01-20 | 2022-07-27 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Thiazolopyrimidones as inhibitors of ddr1/2 and therapeutic uses thereof |
| CN112724157B (zh) * | 2021-01-23 | 2022-04-19 | 中国科学院新疆理化技术研究所 | 二氢噁唑并[5,4-d]吡咯并[1,2-a]嘧啶-9(5H)-酮类衍生物及用途 |
| US20250073242A1 (en) * | 2021-07-30 | 2025-03-06 | The Regents Of The University Of California | Slc26a3 inhibitors and use thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004074270A2 (en) * | 2003-02-21 | 2004-09-02 | Pfizer Inc. | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same |
| US20070155779A1 (en) * | 2006-01-05 | 2007-07-05 | Pfizer Inc | Bicyclic heteroaryl compounds as pde10 inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3888983A (en) * | 1970-08-14 | 1975-06-10 | Seperic | Derivatives of thiazolino-pyrimidin-6-ones, in inducing analgesia |
| US5902815A (en) * | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
| EP0891978B1 (en) | 1997-07-18 | 2002-03-20 | F. Hoffmann-La Roche Ag | 5H-Thiazolo (3,2-a) pyrimidine derivatives |
| WO2007006175A1 (en) | 2005-07-11 | 2007-01-18 | Zte Corporation | Method for implementing channel shared ring protection supported easy failure prevention |
| JP6130061B2 (ja) | 2013-06-19 | 2017-05-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | インドリン−２−オン又はピロロ−ピリジン／ピリミジン−２−オン誘導体 |
| EP3283487B1 (en) | 2015-04-15 | 2019-10-16 | H. Hoffnabb-La Roche Ag | Pyridopyrimidinones and their use as nmda receptor modulators |
-
2014
- 2014-10-08 MX MX2016004540A patent/MX2016004540A/es active IP Right Grant
- 2014-10-08 RS RS20181185A patent/RS58047B1/sr unknown
- 2014-10-08 BR BR112016007563-3A patent/BR112016007563B1/pt active IP Right Grant
- 2014-10-08 HR HRP20181596TT patent/HRP20181596T1/hr unknown
- 2014-10-08 DK DK14781878.5T patent/DK3055315T3/en active
- 2014-10-08 KR KR1020167012236A patent/KR102361108B1/ko active Active
- 2014-10-08 EP EP18177888.7A patent/EP3415519A1/en not_active Withdrawn
- 2014-10-08 SI SI201430905T patent/SI3055315T1/sl unknown
- 2014-10-08 JP JP2016521943A patent/JP6419800B2/ja active Active
- 2014-10-08 PL PL14781878T patent/PL3055315T3/pl unknown
- 2014-10-08 CN CN201480055668.4A patent/CN105612162B/zh active Active
- 2014-10-08 CN CN201810852075.0A patent/CN108929336A/zh active Pending
- 2014-10-08 WO PCT/EP2014/071522 patent/WO2015052226A1/en not_active Ceased
- 2014-10-08 EP EP14781878.5A patent/EP3055315B1/en active Active
- 2014-10-08 ES ES14781878T patent/ES2690355T3/es active Active
- 2014-10-08 CA CA2926830A patent/CA2926830C/en active Active
- 2014-10-08 RU RU2016115487A patent/RU2703273C2/ru active
- 2014-10-08 LT LTEP14781878.5T patent/LT3055315T/lt unknown
- 2014-10-08 HU HUE14781878A patent/HUE040651T2/hu unknown
- 2014-10-08 PT PT14781878T patent/PT3055315T/pt unknown
-
2016
- 2016-04-08 US US15/094,687 patent/US9988400B2/en active Active
-
2018
- 2018-04-25 US US15/962,333 patent/US10647731B2/en active Active
- 2018-10-10 JP JP2018191536A patent/JP2019023217A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004074270A2 (en) * | 2003-02-21 | 2004-09-02 | Pfizer Inc. | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same |
| US20070155779A1 (en) * | 2006-01-05 | 2007-07-05 | Pfizer Inc | Bicyclic heteroaryl compounds as pde10 inhibitors |
Non-Patent Citations (2)
| Title |
|---|
| "A Novel Family of Negative and Positive Allosteric Modulators of NMDA Receptors";Blaise Mathias Costa et al.;《THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS》;20101201;第335卷(第3期);第614-621页 * |
| "Discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as Novel PKM2 Activators";Chuangxing Guo et al.;《Bioorganic & Medicinal Chemistry Letters》;20130401;第23卷(第11期);第3358-3363页 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105612162B (zh) | 作为nmda受体活性的调节剂的噻唑并嘧啶酮类 | |
| TWI771319B (zh) | 吡唑并吡啶化合物及其用途 | |
| CN112074505B (zh) | 作为PI3K-γ抑制剂的氨基吡嗪二醇化合物 | |
| CN119487018A (zh) | 作为irak 4的配体导向降解剂的杂芳基化合物 | |
| TW201512173A (zh) | 炔基醇及其使用方法 | |
| TW201609725A (zh) | 作為抗癌劑之新穎三環化合物 | |
| CN103732597A (zh) | 三环杂环化合物和jak抑制剂 | |
| TW201922721A (zh) | 化學化合物 | |
| TWI614250B (zh) | 作為β－分泌酶抑制劑之環丙基稠合噻嗪－２－胺化合物及其使用方法 | |
| CN111032641A (zh) | 经取代的5-氰基吲哚化合物及其用途 | |
| CN114728975A (zh) | 唑稠合的哒嗪-3(2h)-酮衍生物 | |
| CN105658653A (zh) | 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物 | |
| KR20200070297A (ko) | Rip1 키나아제 억제제로서 사용하기 위한 이환형 화합물 | |
| JP7713461B2 (ja) | 大環状ｒｉｐ２－キナーゼ阻害剤 | |
| JP2016507498A (ja) | Ｃｆｔｒ阻害としての三環式化合物 | |
| TW202016116A (zh) | 作為a2a受體拮抗劑的吡唑並三唑並嘧啶衍生物 | |
| CN114630822B (zh) | 联芳基二氢乳清酸脱氢酶抑制剂 | |
| HK1220202B (zh) | 作为nmda受体活性的调节剂的噻唑并嘧啶酮类 | |
| KR20150036763A (ko) | 축환 복소환 화합물 | |
| TWI907744B (zh) | 包含具有kdm5抑制活性之化合物之醫藥組合物 | |
| HK40117006A (zh) | 新颖杂环化合物 | |
| CN119654326A (zh) | 新颖杂环化合物 | |
| HK40104906A (zh) | 作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1220202 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |